
Biljana Naumovic: Building equitable access should be an all-encompassing priority – not an afterthought or a last step.
Biljana Naumovic, Worldwide Vice President Oncology at The Janssen Pharmaceutical Companies of Johnson & Johnson made the following post on LinkedIn:
“For far too long, we’ve been chasing after equality instead of equity in Clinical Trials. This has left us with a disenchanted reality: a majority of clinical trials do not reflect diverse patient populations that may benefit from cancer therapies being studied.
On the heels of Blood Cancer and Prostate Cancer Awareness Months, consider the fact that Black people are twice as likely to develop multiple myeloma than white people, and yet they only account for 6% of participants in clinical studies. When it comes to prostate cancer, enrollment rates of Black and Hispanic patients have fallen 67% and 44% below what is expected based on the prostate cancer incidence in these communities, according to one study.
It’s clear that we must change course at an urgent pace – but we can’t begin to do so without acknowledging the systemic cause of the issue: inequitable access. Time and again, clinical development plans are approved and executed without considering real-world barriers to participation, such as a lack of insurance, transportation, or diverse representation among clinical trial teams. This is a glaring and negligent mistake that we can’t afford to make. We must proactively account for these barriers and incorporate diverse recruitment strategies into the earliest stages of clinical trial design.
That’s why at Johnson & Johnson Innovative Medicine, we passionately pursue strategic collaborations that aim to put these building blocks in place to ensure equity, not just equality, in clinical trials. Most recently, we collaborated with the American Association for Cancer Research, the FDA and fellow industry peers to outline tangible steps clinical trial sponsors can take to improve diversity in clinical trials, as published in the journal of Clinical Cancer Research. We’ve also collaborated with Stand Up To Cancer to sponsor research teams that aim to develop sustainable, scalable and replicable approaches to remove barriers to Phase 1 and 2 clinical trial participation for patients of all racial and ethnic backgrounds, and with the American Cancer Society to support the advancement of sustainable models of oncology patient navigation, and increase awareness and participation in clinical trials in under-represented communities.
Building equitable access should be an all-encompassing priority – not an afterthought or a last step. It should guide every single decision, from the selection of site locations, to the frequency of visits required of participants, to the materials used to train study teams.
Because it’s only through equity that we can advance innovation and deliver lifesaving treatments to the patients who need them.”
Source: Biljana Naumovic/LinkedIn
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows